镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展

Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases

近年来，全世界前列腺癌的发病率和病死率不断增长，各种治疗方法的研究也进展迅速。镭-223发射的重α粒子（具有＜100μm的超短波）靶向作用于骨转移部位和周围新骨生长区域。镭-223氯化物在药物临床试验中以稳定的安全性显著降低了患者的病死率，成为近来被寄予厚望的转移性去势抵抗性前列腺癌（CRPC）治疗领域的“主角”。2013年美国食品药品管理局已批准镭-223氯化物用于治疗有症状的骨转移、未发现内脏转移的CRPC患者。未来其联合治疗方案将会是研究的重点。

Prostate carcinoma rates and mortalities are increasing worldwide. The therapeutic landscape of castration-resistant prostate carcinoma （CRPC） has changed rapidly. Radium-223 chloride, which is a radiopharmaceutical agent, targets bone metastasis by emitting high-energy alpha-particles with extremely short range （〈100 μm ） . This chemical is effective in reducing mortality without increasing toxicity. Thus, this agent has the potential to become a new alternative for treating patients with CRPC. The Food and Drug Administration approved radium-223 dichloride for treating patients with CRPC, symptomatic bone metastases, and unknown visceral metastatic disease in 2013. Therefore, combination and sequencing strategies will be future research directions.